Kisspeptin

Mechanistically interesting for HPG-axis signaling in women; lacks completed combination trials. Compounding status is contested as of May 2026.

Anthivera’s calibrated five-tier scale — what the strongest evidence on Kisspeptin actually supports today.

1. Preclinical
2. Limited clinicalKisspeptin
3. Multiple human studies
4. Phase 3
5. FDA-approved

Limited clinical: Small open-label or case-report data in humans.

1. 01What evidence is there for Kisspeptin in women specifically — and does that include perimenopausal or postmenopausal cohorts?
2. 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
3. 03What baseline labs do you require before starting, and how often do you monitor?
4. 04What are the realistic timelines and what does “not working for you” look like in practice?

• Peptides for Perimenopause: What the Research Actually Says

  A grounded look at peptides discussed for perimenopause — GH-axis peptides, BPC-157, kisspeptin, collagen, GLP-1 — and where the evidence is strong versus preliminary, with the current 2026 regulatory and safety picture.

• Solace MD

  Higher price band, faster shipping, more personal care — the right fit if cost isn't the primary constraint.

  4.6/5

See the full provider comparison for all peptides side by side.